FDA and the Life-Sciences Industry: Business as Usual?

By Koski, Greg | The Hastings Center Report, September-October 2004 | Go to article overview

FDA and the Life-Sciences Industry: Business as Usual?


Koski, Greg, The Hastings Center Report


On April 15, while most Americans were signing and mailing their 1040s, Rep. Joe Barton (R-TX.), chair of the House Energy and Commerce Committee, issued a press release in which the Food and Drug Administration admitted, for the first time, that an important report regarding concerns for the safety of children taking prescription antidepressants had not been released to the public. As the complex story of the FDA's oversight on antidepressants unfolded, it fueled mounting concerns about the extent to which the pharmaceutical industry has permeated the agency and how it may be influencing the agency's policies, practices and regulatory actions.

The FDA'S admission was contained in a response to an inquiry from Barton and Rep, James Greenwood (R-PA), both of whom served on the Energy and Commerce Committee's Oversight and Investigations Subcommittee. The FDA acknowledged that an internal consultant had concluded that data supported an association between the use of antidepressants and suicidality in children. The internal consultant was Andrew Mosholder, a member of the agency's Office of Drag Safety and a former reviewer for the Division of Neuropharmacological Products of the FDA's Center for Drug Evaluation and Review (CDER). After conducting a seven-month review, Mosholder recommended that the FDA take additional regulatory action. (1)

Not all of the CDER staff had agreed with Mosholder's recommendations. CDER staff decided that, while the tiara from which Mosholder had reached his conclusions should be presented at an upcoming meeting of the FDA's Advisory Committee, having Mosholder do so "would be potentially harmful to public health as it might lead patients who were actually benefiting from the use of these drugs to quit taking them." Instead, Thomas Laughren, also from the Division of Neuropharmacological Products, "presented the same data from which Dr. Mosholder had reached his conclusions," as well as the data from which the Medicines and Healthcare Products Regulatory Agency (the United Kingdom's equivalent of the FDA) had already reached a conclusion essentially identical to Mosholder's--namely, that the association between antidepressant use and suicide in children was substantiated by the evidence. Laughren also described the FDA's plans for further analyzing the data and conducting a more definitive review after that analysis was complete. That analysis, later conducted by independent scientists at Columbia University and released in August (as this essay is being written), fully supported Mosholder's original analysis. (2) Still, the FDA has been slow to take the regulatory action Mosholder recommended.

The events surrounding the Mosholder report and the February 2004 Advisory Committee meeting are now the subject of an ongoing Congressional investigation. (3) One very troubling question is whether Mosholder's conclusions had been inappropriately suppressed, but other, broader concerns may ultimately be even more significant.

The initial inquiry from Representatives Barton and Greenwood noted that concerns about an association between antidepressants and suicide are hardly new. (4) In fact, they date back over twelve years, to when an earlier FDA advisory committee concluded that no association existed. Further, the FDA continued to monitor the situation for more than a decade following its initial determination, during which time several companies submitted data from new clinical trials seeking approval of a pediatric labeling indication for certain antidepressants already approved for use in adults. Barton and Greenwood also called attention to a January 2004 FDA memorandum in which Laughren revealed that twelve of fifteen studies in children with major depressive disorder showed no efficacy compared with placebo--worse yet, possible indicators of increased suicidal risk were apparently found in five of seven pediatric antidepressant trials, according to the congressional letter of inquiry.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

FDA and the Life-Sciences Industry: Business as Usual?
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.